A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
← catalyst calendarNCT04965675 · readout in 16 d
Sponsored by H. Lundbeck A/S (industry) · HLUN-B.CO — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
285estimated
Sites
84
Countries
Argentina, Canada, Italy +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-30 | actual | When the study began enrolling |
| Primary completion | 2026-09-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-07-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Migraine in Children
Interventions
- Drug: Eptinezumab — also filed as Vyepti
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12
measured Baseline, Weeks 1-12
Permalink · HLUN-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed